Epilepsy Pharmacology Begins at the Chloride Gradient
Epilepsy programs need assays that resolve excitability, inhibition, chloride homeostasis, transporter activity, and neuromodulatory signaling without flattening those mechanisms into a single generic readout. ION Biosciences supports NaV, Kv7, GABA-A, KCC2, EAAT2, GAT-1, and GPCR programs with real-time ion flux, chloride, cAMP, calcium, and automated patch clamp workflows.
From Seizure Mechanism to Validated Screening Data
Epilepsy discovery is not one screening problem. Kv7 opener programs need activation protocols that detect shifts in voltage-dependent gating. GABA-A and KCC2 programs depend on chloride movement and inhibitory tone. Transporter and neuromodulatory GPCR programs require readouts that distinguish true target engagement from downstream noise.
ION matches the readout to the seizure mechanism: Superclomeleon for real-time chloride flux, IPG-1 for thallium-free potassium channel pharmacology, ING-2 for sodium channel and transporter activity, and cAMP or calcium assays for GPCR programs. This creates a practical path for cross-validating functional activity across related epilepsy mechanisms while keeping cell systems, controls, and analysis under one CRO workflow.
Assay Services for Epilepsy Discovery Workflows
ION supports epilepsy programs from target feasibility through screening-ready validation, hit confirmation, and orthogonal follow-up. Readout and cell system selection are matched to the seizure mechanism, not a default format.
| Capability | What This Means for Your Program |
|---|---|
| Assay development | Translate the seizure mechanism into a functional assay plan. For Kv7.2/7.3 activator pharmacology, ION has multiple direct and indirect readouts for potassium flux. For GABA-A programs, it means defining whether chloride flux, calcium-based PAM screening, or both are needed. For KCC2, it means establishing the chloride extrusion assay with appropriate controls for transporter-dependent signal. |
| Cell line generation | Configure single- and multi-subunit expression systems, including GABA-A receptor subunit combinations and epilepsy-relevant channel or transporter constructs. |
| Assay optimization | Establish chloride loading conditions, potassium flux signal window, NaV activation protocol, Z’, compound format compatibility, and inter-day reproducibility. For small inhibitory shifts that matter in disease biology, optimization determines whether the assay will detect a therapeutic window or miss it. |
| Assay validation | Benchmark with clinically characterized anti-seizure agents and pathway reference compounds to establish a defined pharmacological frame of reference before library screening. Known clinical compounds anchor the assay so new compound activity can be interpreted against a meaningful context. |
| Compound screening | Primary screening, concentration-response profiling, hit confirmation, counter-screening, and selectivity panel assays across NaV, Kv7, GABA-A, KCC2, EAAT2, GAT-1, and GPCR targets. |
| Orthogonal validation | Automated patch clamp for priority hits when gating mechanism, voltage dependence, or subunit selectivity needs biophysical resolution beyond fluorescence data. |
| Pharmacology-ready data packages | Activity calls, IC50 or EC50 values, curves, Z’ and QC metrics, subtype comparison where relevant, and recommended next-stage decisions formatted for go/no-go review. |
Ion Channels, Transporters, and GPCRs at the Center of Seizure Biology
ION supports mechanism-matched assay strategies for the major target classes involved in seizure biology, inhibitory control, and neuromodulation. For feasibility-stage targets, readout selection depends on target biology, cell system, controls, and activation or inhibition mechanism.
Target Coverage for Epilepsy Programs
These are the targets ION can mobilize without a feasibility delay. Cell lines, readout infrastructure, and reference pharmacology are already established for the targets below. For targets not yet in the validated inventory, ION can assess feasibility and develop a screening-compatible workflow.
| Target Area | In-House Targets | Readouts | Use Cases |
|---|---|---|---|
| NaV channels | NaV1.3 (SCN3A) | Sodium flux, lithium flux, APC, membrane potential | Inhibitor screening, gain-of-function mutation pharmacology, state-dependent profiling |
| Kv7 potassium channels | Kv7.2/Kv7.3 (KCNQ2/KCNQ3) | Thallium-free potassium flux, thallium flux, membrane potential, APC | Channel opener and blocker screening, voltage-dependent pharmacology, channelopathy models |
| Inhibitory chloride signaling | GABA-A receptors, KCC2 (SLC12A5) | Chloride flux, thallium-free potassium flux, thallium flux, APC | PAM and NAM screening, chloride cotransporter pharmacology, inhibitory tone assays |
| Glutamate transporters | EAAT2 (SLC1A2) | Sodium flux, thallium flux, membrane potential | Transporter activator and inhibitor profiling, glutamate clearance pharmacology |
| GABA transporters | GAT-1 (SLC6A1) | Sodium flux, substrate uptake assay | Transporter inhibitor and uptake pharmacology |
| Neuromodulatory GPCRs | Adenosine A2A (ADORA2A), CB1 (CNR1), CB2 (CNR2) | cAMP, calcium flux, biased Gα15 coupling (calcium), Gi-GIRK thallium flux | Agonist, antagonist, and inverse agonist profiling; seizure threshold modulation programs |
Why Partner With ION for Epilepsy Drug Discovery?
Epilepsy drug discovery requires readout diversity that most CROs cannot offer from a single platform. Direct chloride flux, thallium-free potassium flux, sodium flux, and pathway-matched GPCR assays are available from the same team and the same instrument.
Thallium-Free Kv7.2/Kv7.3 Pharmacology at Screening Scale
Conventional potassium channel screening relies on thallium-based flux assays because standard fluorescent indicators do not effectively discriminate K⁺ from other cations at physiological concentrations. Thallium permeates potassium channels and drives the fluorescent signal, but it introduces biosafety handling requirements, complicates assay conditions at low concentrations, and may not recapitulate K⁺-selective pharmacology with complete fidelity. For Kv7 channel opener programs, activation protocol design is equally critical: compounds that left-shift the voltage dependence of activation are only detectable if the assay includes an appropriate depolarizing stimulus to drive channel opening under controlled conditions.
- HEK293 Kv7.2/Kv7.3 stable co-expression cell line
- IPG-1 thallium-free potassium flux indicator, 384-well WaveFront Panoptic format
- KCl depolarization activation protocol to drive Kv7 channel opening
- XEN1101 confirmed to left-shift voltage dependence of activation in a concentration-dependent manner
- Pharmacological benchmarking against retigabine as an additional Kv7 opener reference
Epilepsy Program FAQs
What epilepsy-relevant targets can ION support?
How does ION measure chloride flux, and why does it matter for epilepsy programs?
What is the thallium-free potassium assay, and why is it the right format for Kv7 programs?
Can ION support GABA-A receptor pharmacology, and how are multi-subunit configurations handled?
How does ION handle programs that need more than one assay format for the same epilepsy target?
Can ION run assays for neuromodulatory GPCRs such as adenosine A2A or CB1 in the context of epilepsy?
Building an Epilepsy Assay Program?
Share the target, mechanism, compound class, and decision criteria. ION can scope a practical path from feasibility through screening-ready validation, with readout selection and controls matched to seizure biology.